The possibilities of “Exportal” in the treatment of patients with liver cirrhosis and hepatic encephalopathy

Ataeva Abidat Akhmalutdinovna, Ataeva Jennet Akhmaiutdinovna

The development of hepatic encephalopathy in patients with liver cirrhosis is a very acute problem, since greatly affects the quality of life of patients. Objective: to assess the effect of the drug "Exportal" on the clinical picture and the quality of life of patients with cirrhosis and hepatic encephalopathy. Materials and methods: a survey of 77 patients diagnosed with liver cirrhosis. Among them - women prevailed - 46 people (59.7%), men - 31 people (40.2%). The average age of patients included in the analysis was 55.7 ± 6.4 years (26-67). Disease duration on average 7.3 ± 4.4 years (2-34). All patients took the drug Exportal ("FPK PharmVILAR"). The comparison group consisted of patients with a diagnosis of liver cirrhosis who received exclusively concomitant therapy — 50 people. Results: in the patients of the main group, the clinical indicators improved in the form of a decrease in the degree of hepatic encephalopathy. When assessing the impact of the treatment on the quality of life of patients, we found statistically significant changes only in terms of vital activity. Thus, the administration of the drug “Exportal” is very promising in the treatment of patients with cirrhosis of the liver and hepatic encephalopathy, but its effect on the quality of life requires more prolonged observation.

Keywords:liver cirrhosis, intestinal microbiota, hepatic encephalopathy, exportal, quality of life